Kenvue Inc. KVUE
At Kenvue, our purpose is to realize the extraordinary power of everyday care. As a global leader at the intersection of healthcare and consumer goods, we are the world's largest pure-play consumer health company by revenue with $15.1 billion in Net sales in the fiscal year 2025. By combining the power of science with meaningful consumer insights and our digital strategy, we empower consumers to live healthier lives every day. Built on more than a century of heritage and trusted by generations, our differentiated portfolio of iconic brands—including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena®, Nicorette®, Tylenol®, and Zyrtec®—is backed by science and recommended by healthcare professionals, which further reinforces our consumers' connections to our brands.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $15.12B | $15.46B | $15.44B | $14.95B | $15.05B | — |
| Cost of revenue | $6.33B | $6.50B | $6.80B | $6.67B | $6.63B | — |
| Gross profit | $8.79B | $8.96B | $8.64B | $8.29B | $8.42B | — |
| R&D | $382.0M | $408.0M | $399.0M | $375.0M | $355.0M | — |
| SG&A | $6.09B | $6.33B | $6.14B | $5.63B | $5.48B | — |
| Operating income | $2.41B | $1.84B | $2.51B | $2.67B | $2.92B | — |
| Interest expense | — | — | $250.0M | $0 | $0 | — |
| Pre-tax income | $2.00B | $1.42B | $2.19B | $2.64B | $2.92B | — |
| Income tax | $529.0M | $385.0M | $526.0M | $573.0M | $847.0M | — |
| Net income | $1.47B | $1.03B | $1.66B | $2.06B | $2.08B | — |
| EPS, basic | 0.77 | 0.54 | 0.90 | 1.20 | 1.21 | — |
| EPS, diluted | 0.76 | 0.54 | 0.90 | 1.20 | 1.21 | — |
| Shares, diluted (wtd. avg.) | 1.92B | 1.92B | 1.85B | 1.72B | 1.72B | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $1.06B | $1.07B | $1.38B | $1.23B | $740.0M | $618.0M |
| Receivables | $2.38B | $2.17B | $2.07B | $2.12B | — | — |
| Inventory | $1.67B | $1.59B | $1.85B | $2.23B | — | — |
| Total current assets | $5.70B | $5.53B | $6.14B | $5.88B | — | — |
| Property, plant and equipment | $2.21B | $1.85B | $2.04B | $1.82B | — | — |
| Goodwill | $9.51B | $8.84B | $9.27B | $9.19B | $9.81B | — |
| Other intangibles | $8.69B | $8.47B | $9.62B | $9.85B | — | — |
| Total assets | $27.08B | $25.60B | $27.85B | $27.32B | — | — |
| Accounts payable | $2.47B | $2.25B | $2.49B | $1.83B | — | — |
| Short-term debt | $750.0M | $750.0M | $0 | $0 | — | — |
| Total current liabilities | $5.95B | $5.74B | $5.48B | $3.93B | — | — |
| Long-term debt | — | — | $7.69B | $0 | — | — |
| Total liabilities | $16.31B | $15.93B | $16.64B | $7.35B | — | — |
| Retained earnings | -$204.0M | -$93.0M | $429.0M | $0 | — | — |
| Total equity | $10.77B | $9.67B | $11.21B | $19.97B | $20.49B | $18.40B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $2.20B | $1.77B | $3.17B | $2.52B | $334.0M | — |
| Depreciation and amortisation | $557.0M | $622.0M | $627.0M | $644.0M | $731.0M | — |
| Stock-based compensation | $136.0M | $254.0M | $188.0M | $137.0M | $141.0M | — |
| Capital expenditure | $475.0M | $434.0M | $469.0M | $375.0M | $295.0M | — |
| Investing cash flow | -$436.0M | -$425.0M | -$488.0M | -$390.0M | -$171.0M | — |
| Financing cash flow | -$1.84B | -$1.56B | -$2.53B | -$1.58B | $0 | — |
| Dividends paid | $1.58B | $1.55B | $766.0M | $0 | $0 | — |
| Buybacks | $197.0M | $235.0M | $7.0M | $0 | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001944048-26-000085.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $15.05B | $14.95B | $15.44B | $15.46B | $15.12B |
| Gross profit | — | $8.42B | $8.29B | $8.64B | $8.96B | $8.79B |
| Net income | — | $2.08B | $2.06B | $1.66B | $1.03B | $1.47B |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Restructuring or exit costs A restructuring: layoffs, a plant closure, a business being wound down. Item 2.05
- Officer or director change Item 5.02
- Shareholder vote Item 5.07
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2844
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| CL | COLGATE PALMOLIVE CO | $74.97B | 35.8x | 1.4% |
| EL | ESTEE LAUDER COMPANIES INC | $39.37B | 217.3x | 5.0% |
| ELF | e.l.f. Beauty, Inc. | $6.74B | 259.6x | 24.6% |
| IPAR | INTERPARFUMS INC | $3.69B | 22.0x | 2.5% |
| COTY | COTY INC. | $2.84B | — | -1.5% |
| EPC | EDGEWELL PERSONAL CARE Co | $1.29B | 52.9x | -1.3% |
| WALD | Waldencast plc | $100.3M | — | -0.7% |
| SLSN | SOLESENCE, INC. | $56.5M | 40.0x | 18.6% |